

Horizon collaborates with Blueprint Medicines, 11/13

Horizon Discovery has signed a research service agreement with Blueprint Medicines, a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will support Blueprint's New Targets discovery platform by deploying its X-Man isogenic cell lines.

Horizon will use its proprietary platform to screen a selection of Blueprint's kinase inhibitor tool compounds on a panel of 26 X-Man isogenic cell lines. Performing screens on X-Man cell lines will provide valuable insights into elucidating synthetic lethal interactions with approximately 100 kinase targets in various cancer subtypes.

Financial terms were not disclosed.

[Horizon Discovery](#), 44 (0) 12 2365 5580

[Blueprint Medicines](#), 617-374-7580